Compass Therapeutics (NASDAQ:CMPX) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of Compass Therapeutics (NASDAQ:CMPX) from a hold rating to a sell rating in a research note released on Sunday.

CMPX has been the topic of a number of other research reports. William Blair began coverage on Compass Therapeutics in a research note on Monday, January 5th. They issued an “outperform” rating on the stock. Raymond James Financial reiterated an “outperform” rating and issued a $9.00 target price on shares of Compass Therapeutics in a report on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Wednesday, January 21st. Citigroup assumed coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an “outperform” rating for the company. Finally, JMP Securities set a $10.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Compass Therapeutics has an average rating of “Moderate Buy” and an average price target of $12.46.

Compass Therapeutics Price Performance

Compass Therapeutics stock opened at $6.52 on Friday. Compass Therapeutics has a 12 month low of $1.33 and a 12 month high of $6.88. The company has a fifty day moving average price of $5.56 and a two-hundred day moving average price of $4.39. The company has a market cap of $1.16 billion, a PE ratio of -14.49 and a beta of 1.46.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds have recently made changes to their positions in the business. Strs Ohio bought a new position in shares of Compass Therapeutics in the first quarter worth about $34,000. Creative Planning acquired a new stake in shares of Compass Therapeutics in the second quarter valued at approximately $30,000. XTX Topco Ltd bought a new position in Compass Therapeutics in the 2nd quarter worth approximately $84,000. Invesco Ltd. lifted its holdings in Compass Therapeutics by 58.1% during the 2nd quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock worth $153,000 after buying an additional 21,578 shares in the last quarter. Finally, Vivo Capital LLC lifted its stake in shares of Compass Therapeutics by 70.0% during the second quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock valued at $15,713,000 after acquiring an additional 2,487,443 shares during the period. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.